
Zymeworks Inc. (NASDAQ:ZYME – Free Report) – Equities researchers at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for shares of Zymeworks in a research note issued to investors on Tuesday, November 10th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of $1.19 per share for the year, down from their previous forecast of $1.51. HC Wainwright currently has a “Buy” rating and a $56.00 target price on the stock. The consensus estimate for Zymeworks’ current full-year earnings is $1.31 per share. HC Wainwright also issued estimates for Zymeworks’ Q4 2026 earnings at $0.05 EPS, Q1 2027 earnings at $0.64 EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at $0.33 EPS, Q4 2027 earnings at ($0.78) EPS and FY2027 earnings at ($0.39) EPS.
Several other equities analysts have also weighed in on ZYME. Citigroup boosted their target price on shares of Zymeworks from $39.00 to $44.00 and gave the company a “buy” rating in a report on Wednesday. Wells Fargo & Company raised their price target on shares of Zymeworks from $37.00 to $40.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Citizens Jmp lifted their price target on shares of Zymeworks from $32.00 to $39.00 and gave the company a “market outperform” rating in a research report on Friday. B. Riley Financial reiterated a “buy” rating and issued a $44.00 price objective (up from $40.00) on shares of Zymeworks in a report on Monday, August 10th. Finally, Wolfe Research assumed coverage on Zymeworks in a research report on Thursday, September 17th. They issued an “outperform” rating for the company. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Zymeworks has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.
Zymeworks Price Performance
Shares of ZYME stock opened at $26.24 on Thursday. The firm’s 50-day moving average is $27.32 and its two-hundred day moving average is $25.48. Zymeworks has a 12 month low of $18.20 and a 12 month high of $31.97. The company has a market capitalization of $1.81 billion, a PE ratio of 50.46 and a beta of 1.32.
Zymeworks (NASDAQ:ZYME – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported $2.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.27 by $0.01. Zymeworks had a net margin of 16.10% and a return on equity of 22.23%. The firm had revenue of $512.92 million during the quarter, compared to analyst estimates of $227.40 million. During the same quarter in the prior year, the firm posted ($0.26) earnings per share. Zymeworks’s quarterly revenue was up 828.7% on a year-over-year basis.
Insider Activity
In related news, EVP Adam Schayowitz sold 13,832 shares of the business’s stock in a transaction dated Friday, October 9th. The shares were sold at an average price of $25.85, for a total value of $357,557.20. Following the sale, the executive vice president directly owned 23,205 shares in the company, valued at approximately $599,849.25. The trade was a 37.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 37.73% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the stock. Rubric Capital Management LP increased its position in shares of Zymeworks by 21.7% during the first quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company’s stock valued at $175,280,000 after acquiring an additional 1,250,000 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Zymeworks in the 2nd quarter valued at approximately $111,122,000. Perceptive Advisors LLC lifted its holdings in shares of Zymeworks by 7.6% in the 1st quarter. Perceptive Advisors LLC now owns 3,510,078 shares of the company’s stock worth $87,892,000 after acquiring an additional 248,228 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Zymeworks by 20.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,508,069 shares of the company’s stock worth $39,949,000 after acquiring an additional 256,042 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of Zymeworks by 6.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 743,898 shares of the company’s stock worth $18,627,000 after acquiring an additional 43,896 shares during the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.
Key Zymeworks News
Investors following ZYME have been watching these news items:
- Positive Sentiment: Citizens JMP raised its price target to $39 from $32 and assigned a “market outperform” rating, implying substantial upside from the referenced $26.24 share price. TickerReport article
- Positive Sentiment: Separate reports cited a higher TD Cowen price target, a bullish forecast from Truist, and Zymeworks reaching a new 52-week high after better-than-expected earnings. TD Cowen price target report Truist forecast report New 52-week high report
- Negative Sentiment: HC Wainwright cut its estimates across several upcoming quarters, lowering its FY2026 EPS forecast to $1.19 from $1.51 and moving its FY2027 outlook from $1.32 profit to a projected $0.39 loss. The analyst retained a Buy rating and $56 target, but the revisions signal a less favorable earnings outlook beyond the recent quarter.
Zymeworks Company Profile
Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.
Featured Articles
- Five stocks we like better than Zymeworks
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.
